Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 85,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV-1-infection
Interventions: Albuvirtide, 3BNC117, Baseline ART; Drug
Lead sponsor: Frontier Biotechnologies Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 7
States / cities: Palm Springs, California • San Francisco, California • Ft. Pierce, Florida + 4 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Placebo, GM-CSF; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 3
States / cities: Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan

Conditions: Hematologic Malignancies
Interventions: UCB and HPDSC; Procedure
Lead sponsor: Celgene Corporation; Industry
Eligibility: Up to 55 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Prostate Cancer
Interventions: Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy; Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 106
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more

Conditions: Open Fracture Wounds
Interventions: Saline Solution, Soap solution, Gravity Flow Irrigation, Low Pressure Irrigation, High Pressure; Procedure
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 14 Years to 85 Years
Enrollment: 2,540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 11 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: AMG 160; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Cognitive Decline
Interventions: Physical Activity; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 55 Years to 79 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: HIV
Interventions: Evolution: Young Women Taking Charge and Growing Stronger; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 24 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Tampa, Florida • Chicago, Illinois • Baltimore, Maryland

Conditions: Plaque Psoriasis
Interventions: DFD01 Spray; Drug
Lead sponsor: Primus Pharmaceuticals; Industry
Eligibility: 12 Years to 16 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Encino, California • Irvine, California • San Diego, California + 5 more

Conditions: Central Nervous System B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
Interventions: Ibrutinib, Nivolumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer, Lung Cancer
Interventions: celecoxib, adjuvant therapy; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: Chicago, Illinois • Chapel Hill, North Carolina

Conditions: Healthy Volunteer
Interventions: SAGE-718, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Neoplasms
Interventions: RO6895882; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Racial/Ethnic Minorities on Dialysis
Interventions: Active Comparator: peer navigator, Placebo Comparator: Control Arm (standard of care); Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Diabetes Mellitus, Type 1
Interventions: Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo; Drug
Lead sponsor: vTv Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 47
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Concord, California + 41 more

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Azacitidine, Enasidenib Mesylate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sedentary Lifestyle
Interventions: Frequent sit-to-stands, Stand More; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 55 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Tinea Cruris, Jock Itch
Interventions: NAFT-500, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Anetumab Ravtansine, Bevacizumab, Paclitaxel; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 22
States / cities: Orange, California • Aurora, Colorado • Coral Gables, Florida + 19 more

Conditions: Smoking, Smoking Cessation, HIV
Interventions: Nicoderm C-Q Transdermal Product, Adherence to Antiretroviral Therapy Counseling, Behavioral Smoking Cessation Counseling, "Crave-to-Quit" app, vDOT "emocha" app; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 2 Months to 3 Months
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Search by objective public record fields.

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

A Randomized Trial of GM-CSF in Patients With ALI/ARDS

A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Fluid Lavage of Open Wounds

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Yoga, Aerobic and Stretching Exercise Effects on Neurocognition

Development of an Empowerment Intervention for Young Women Living With HIV

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

Prosperando: Fostering Resilience on Dialysis

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Sedentary Behavior Interrupted: A Trial of Acute Effects on Biomarkers of Healthy Aging

Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients

Differences Between Breastfed and Formula Fed Infants